The latest market report published by Credence Research, Inc., the global market for recombinant plasma protein therapeutics is set to grow from US$ 7,788.9 million in 2017 to US$ 15,910.5 million by 2026 with a CAGR increase of 8.3 per cent from 2018 to 2026.
Blood clotting disorders occur at a rate of 1 in 1,000 worldwide, with many patients remaining undiagnosed throughout their lifetime. Human plasma-derived proteins are completely replaced by recombinant coagulation factors due to lack of transmission of blood-borne infectious diseases. The high titer ratio of protein production using recombinant technology provides positive support for the growth of the recombinant plasma protein therapeutic market.
Browse the full report at “Recombinant Plasma Protein Therapeutics Market”
Recombinant coagulation factor VIII is the leading drug class in the recombinant plasma protein therapeutic market. Human plasma-derived proteins and desmopressin have been completely replaced in the treatment of severe and mild hemophilia A. Recombinant coagulation factor IX will gain momentum in the near future due to the recent approval of Rebinyn (Novo Nordisk) for the treatment of long-term hemophilia B.
Hemophilia A currently dominates the indication segment of the recombinant plasma protein therapeutic market. The high prevalence rate and the occurrence of severe form in 70 per cent of patients diagnosed is driving their market growth. Due to the USFDA approval of VONVENDI (Shire, Plc.) in April 2018, Von Willebrand disease will register outstanding growth in the near future.
Chinese ovarian hamster will be the leading and fastest growing segment of the recombinant plasma protein therapeutic market for the entire forecast period. Its inherent features, such as ability to adapt the growing conditions of serum-free suspension, powerful gene amplification and post-translational modification capability compared to other cell lines used in recombinant protein synthesis.
North America, with a market share of 40%, is the leading regional segment of the recombinant plasma protein therapeutic market. The increasing prevalence of hemophilia A and the existence of a comprehensive network of federally funded hemophilia treatment centers are major factors influencing its market growth. Europe with a 30 per cent share is in second place due to the domicile of key players such as CSL Behring, Novo Nordisk and Bayer AG. Asia Pacific has a 20 per cent share and will eventually grow in the coming years due to the increased adoption of recombinant biotechnology for the production of coagulation factors.
Biotechnology companies manufacturing recombinant plasma proteins are Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc. and Viropharma Biologics, Inc.
Key Market Movements:
- Increasing diagnosis of blood clotting disorders such as hemophilia A, hemophilia B and Von Willebrand disease
- Existence of comprehensive network of federally or centrally funded hemophilia treatment centers in the developed nations such as North America and Europe
- Recent approval of recombinant coagulation factors by the USFDA has completely replaced human derived plasma proteins to treat blood clotting disorders
By Drug Class Type
- Recombinant Factor VIII
- Recombinant Factor IX
By Cell Line Type
- Chinese Hamster Ovary
- Baby Hamster Kidney
- Human Embryonic Kidney
By Indication Type
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
By Geography Segment
- North America (U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (Middle East & Africa, Latin America)